Antengene Secures Regulatory Approval for Critical Phase III CLINCH-3 Trial of ATG-022 in China
Significant Progress for Antengene’s CLDN18.2+ Gastric Cancer Therapy
Key Highlights
- Regulatory Approval: Antengene Corporation Limited has received endorsement from China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) to initiate the pivotal Phase III CLINCH-3 study of ATG-022, an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2).
- Trial Details: The CLINCH-3 study will be a randomized, controlled, open-label, multicenter clinical trial. It will compare ATG-022 against treatment options chosen by investigators for patients with CLDN18.2+ advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Scope: The trial will begin in China and is planned as a multi-regional clinical trial (MRCT), signaling Antengene’s global ambitions for this therapy.
- Primary Endpoints: The main endpoints are progression-free survival (PFS) as assessed by an independent review committee and overall survival (OS). Secondary endpoints include objective response rate (ORR), duration of response (DOR), disease control rate (DCR), safety, and other clinical measures.
- Purpose: This pivotal registrational study is intended to support a future marketing approval application for ATG-022 as monotherapy for the targeted cancer indications.
Potential Share Price Sensitivity & Investor Considerations
- Regulatory Milestone: Securing endorsement for a pivotal Phase III trial is a major regulatory milestone. This approval moves ATG-022 significantly closer to potential commercialization, which could positively impact Antengene’s share value if the study proves successful.
- Risks and Uncertainties: The company explicitly cautions that there is no guarantee ATG-022 will be successfully developed or marketed. Investors should be aware that clinical trial failure, safety concerns, or regulatory delays could negatively affect share prices.
- Global Expansion: The planned multi-regional clinical trial underscores Antengene’s strategy to expand its footprint beyond China, which, if successful, could further enhance its market value and investor confidence.
- Leadership and Board: The announcement was made by Dr. Jay Mei, Chairman, with executive directors including Mr. Donald Andrew Lung and independent non-executive directors Ms. Jing Qian, Mr. Sheng Tang, and Dr. Rafael Fonseca. This experienced leadership team may reassure investors regarding the direction and execution of the trial.
Company and Pipeline Overview
Antengene is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. The company’s pipeline includes several investigational candidates, such as:
- ATG-022 (CLDN18.2 ADC) – target of the pivotal Phase III study
- ATG-037 (oral CD73 inhibitor)
- ATG-101 (PD-L1 x 4-1BB bispecific antibody)
- ATG-125 (B7-H3 × PD-L1 bispecific ADC)
- ATG-207 (αCD3-TGF-β bifunctional fusion protein)
- T cell engager programs developed via proprietary AnTenGager® platform, targeting a broad range of cancer and autoimmune diseases
Antengene has obtained 32 IND approvals in the U.S. and Asia, and new drug application (NDA) approvals in 10 Asia-Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in several regions and included in national insurance schemes in five markets, highlighting its commercial viability and reach.
Forward-Looking Statements and Investor Caution
The company has issued a forward-looking statement, noting that actual results may differ materially from expectations. Investors are advised to exercise caution, as future outcomes depend on ongoing trial results, regulatory reviews, and other unpredictable factors.
Conclusion
The CDE approval for the pivotal Phase III CLINCH-3 study marks a significant advancement for Antengene’s pipeline and could be a catalyst for share price movement, contingent on positive trial outcomes and regulatory progress. Investors should monitor developments closely, given both the opportunities and risks involved.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information provided is accurate as of the date of publication and may be subject to change.
Antengene 獲中國藥監局 CDE 批准開展關鍵 III 期 CLINCH-3 試驗
針對 CLDN18.2+ 胃癌新療法的重大進展
重點摘要
- 監管批准： Antengene 公司已獲中國國家藥品監督管理局（NMPA）藥品審評中心（CDE）批準，開展 ATG-022（Claudin 18.2 抗體藥物偶聯物）III 期關鍵臨床試驗 CLINCH-3。
- 試驗詳情： CLINCH-3 研究是一項隨機、對照、開放標籤、多中心 III 期臨床試驗，將比較 ATG-022 與研究者選擇的治療方案，用於 CLDN18.2+ 晚期胃或胃食管接合部（GEJ）腺癌患者。
- 範圍： 試驗將首先在中國啟動，並計劃作為多區域臨床試驗（MRCT），體現 Antengene 的全球戰略布局。
- 主要終點： 試驗主要終點為獨立審查委員會評估的無進展生存期（PFS）和總生存期（OS）。次要終點包括客觀反應率（ORR）、反應持續時間（DOR）、疾病控制率（DCR）、安全性及其他指標。
- 目的： 此 III 期註冊性試驗將為 ATG-022 單藥治療 CLDN18.2+ 晚期胃或 GEJ 腺癌未來申請上市批准提供支持。
對股東及股價敏感事項
- 監管里程碑： 獲批開展關鍵 III 期試驗對 Antengene 來說是重大監管進展，如試驗成功將有望推動 ATG-022 商業化，對股價可能有正面影響。
- 風險與不確定性： 公司明確提醒，ATG-022 最終能否成功開發及上市仍存在不確定性。臨床失敗、安全性問題或監管延遲均可能對股價帶來負面影響。
- 全球擴展： 計劃開展多區域臨床試驗彰顯公司全球布局，若順利推進，將增強市場信心及公司估值。
- 管理團隊： 公告由董事會主席梅建明博士發布，執行董事包括 Donald Andrew Lung，獨立非執行董事包括錢婧、唐晟及 Rafael Fonseca 博士，有豐富經驗的管理層有助執行臨床試驗。
公司及產品管線介紹
Antengene 是一家全球型、以研發為驅動、商業化階段的生物科技公司，致力於開發首創及最佳療效的藥物，滿足重大未被滿足的醫療需求。公司管線包括：
- ATG-022（CLDN18.2 ADC）——本次 III 期試驗主角
- ATG-037（口服 CD73 抑制劑）
- ATG-101（PD-L1 x 4-1BB 雙特異性抗體）
- ATG-125（B7-H3 × PD-L1 雙特異性 ADC）
- ATG-207（αCD3-TGF-β 雙功能融合蛋白）
- 自主 AnTenGager® 平台開發的 T 細胞激活劑，涵蓋多種腫瘤及自身免疫疾病
Antengene 已在美國及亞洲取得 32 個 IND 批准，並在亞太 10 個市場取得 NDA 批准。其核心商業產品 XPOVIO®（selinexor）已在多地上市，並納入五個市場的國家醫保，展現商業潛力及市場覆蓋。
前瞻性聲明及股東提示
公司已發出前瞻性聲明，提醒投資者實際結果可能與預期有重大差異。投資者應謹慎行事，持續關注臨床進展、監管審批及其他不可預測因素。
總結
CDE 批准 CLINCH-3 III 期試驗標誌著 Antengene 管線重大進展，若試驗結果正面及監管順利推進，將成為推動股價的重要催化劑。投資者應密切留意後續動態，謹慎評估機會與風險。
免責聲明： 本文章僅供參考，不構成任何投資建議。投資者應自行進行盡職調查，並諮詢專業顧問後再作出投資決定。本文資訊截至發布日，或會隨時更新。
